ArticleCurrent research in pharmacology and drug discovery2022

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.

Amit A Joharapurkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.